Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies (Q54652652)

2 June 2018

editorial

0 references

title

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies (English)

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

4 July 2024

1 reference

2

Bristi Basu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807783

4 July 2024

3

Johann S. de Bono

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20807783

4 July 2024

author name string

David Olmos

1

1 reference

2 June 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20807783

4 July 2024

publication date

31 August 2010

1 reference

2 June 2018

Molecular Cancer Therapeutics

published in

1 reference

2 June 2018

volume

9

1 reference

2 June 2018

issue

9

1 reference

2 June 2018

page(s)

2447-2449

1 reference

2 June 2018

IGF-1 Receptor Levels and the Proliferation of Young and Senescent Human Fibroblasts

cites work

1

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Insulin and insulin-like growth factor signalling in neoplasia

4 July 2024

2

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor

4 July 2024

3

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

4 July 2024

4

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study

4 July 2024

5

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo

4 July 2024

8

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Mapping of the insulin-like growth factor II binding site of the Type I insulin-like growth factor receptor by alanine scanning mutagenesis

4 July 2024

9

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response

4 July 2024

10

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

4 July 2024

11

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells

4 July 2024

13

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

4 July 2024

14

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma

4 July 2024

16

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

The history of cancer epigenetics

4 July 2024

17

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Structural biology of insulin and IGF1 receptors: implications for drug design

4 July 2024

18

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy

4 July 2024

19

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling

4 July 2024

20

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

4 July 2024

21

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

4 July 2024

22

1 reference

https://api.crossref.org/works/10.1158/1535-7163.MCT-10-0719

4 July 2024

Identifiers

1 reference

2 June 2018

1 reference

2 June 2018